瑞士精神病学队列GWAS发现四个与精神药物致体重增加相关的新位点
在1135名接受抗精神病药、心境稳定剂或部分抗抑郁药治疗的PsyMetab队列患者中,对治疗早期(≤6个月)BMI变化进行GWAS分析,发现四个新位点与治疗期间BMI改变在全基因组显著性水平相关(p < 5 × 10-8)。在1622名UK Biobank接受精神药物治疗的参与者中,rs7736552与BMI斜率呈一致关联(p = 0.017)。
要点
- 四个新位点:rs7736552(MAN2A1附近)、rs11074029(SLCO3A1内)、rs117496040(DEFB1附近)、rs7647863(IQSEC1内)。
- UK Biobank复制分析中rs7736552与BMI斜率一致关联(p = 0.017)。
- 研究聚焦治疗早期≤6个月BMI变化,提示精神药物代谢副作用具有遗传易感性。
核心结论
- 在瑞士精神病学纵向队列中鉴定出四个与精神药物诱导的BMI改变在全基因组显著性水平相关的新位点。
- rs7736552与BMI斜率的关联在UK Biobank接受精神药物治疗的参与者中得到复制(p = 0.017)。
研究设计与样本
- 研究为GWAS分析,纳入PsyMetab队列1135名接受抗精神病药、心境稳定剂或部分抗抑郁药治疗的患者。
- 分析治疗早期(≤6个月)BMI变化,考虑六种高度相关的BMI表型(不同治疗时长后的BMI变化与BMI斜率)。
- 复制分析纳入1622名UK Biobank接受精神药物治疗的参与者。
主要发现
- 四个新位点与治疗期间BMI改变在全基因组显著性水平相关(p < 5 × 10-8):rs7736552(MAN2A1附近)、rs11074029(SLCO3A1内)、rs117496040(DEFB1附近)、rs7647863(IQSEC1内)。
- 四个位点与替代BMI变化表型的关联显示一致效应。
- UK Biobank复制分析中rs7736552与BMI斜率呈一致关联(p = 0.017)。
关键数值与推荐
- 全基因组显著性阈值定义为p < 5 × 10-8。
- 复制分析中rs7736552与BMI斜率的关联p = 0.017。
临床怎么用
- 研究提示精神药物所致体重增加存在遗传易感位点,未来或可助力识别高风险患者。
- 目前结果尚需在更大队列中复制,暂不宜直接用于临床基因检测或个体化用药决策。
局限性
- 作者指出既往GWAS样本量小或仅限单一抗精神病药,本研究仍需未来在更大队列中复制这些关联。
- 复制分析仅UK Biobank中rs7736552与BMI斜率达到一致关联,其余位点未报告复制结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients suffering from mental disorders are at high risk of developing cardiovascular diseases, leading to a reduction in life expectancy. Genetic variants can display greater influence on cardiometabolic features in psychiatric cohorts compared to the general population. The difference is possibly due to an intricate interaction between the mental disorder or the medications used to treat it and metabolic regulations. Previous genome wide association studies (GWAS) on antipsychotic-induced weight gain included a low number of participants and/or were restricted to patients taking one specific antipsychotic. We conducted a GWAS of the evolution of body mass index (BMI) during early (i.e., ≤ 6) months of treatment with psychotropic medications inducing metabolic disturbances (i.e., antipsychotics, mood stabilizers and some antidepressants) in 1135 patients from the PsyMetab cohort. Six highly correlated BMI phenotypes (i.e., BMI change and BMI slope after distinct durations of psychotropic treatment) were considered in the analyses. Our results showed that four novel loci were associated with altered BMI upon treatment at genome-wide significance (p < 5 × 10-8): rs7736552 (near MAN2A1), rs11074029 (in SLCO3A1), rs117496040 (near DEFB1) and rs7647863 (in IQSEC1). Associations between the four loci and alternative BMI-change phenotypes showed consistent effects. Replication analyses in 1622 UK Biobank participants under psychotropic treatment showed a consistent association between rs7736552 and BMI slope (p = 0.017). These findings provide new insights into metabolic side effects induced by psychotropic drugs and underline the need for future studies to replicate these associations in larger cohorts.
引用
- Sjaarda J, Delacrétaz A, Dubath C, et al. Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis. Mol Psychiatry. 2023. PMID: 37173452. doi:10.1038/s41380-023-02082-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。